Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Maia – page 7

691 clinical trials in Maia, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Maia at a glance
691
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

691 trials in Maia

Open in trial search

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:EIK1005 sodium
  • Sponsor:Eikon Therapeutics Inc.

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Asthma

Recruiting

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GB-0895
  • Sponsor:Generate Biomedicines Inc.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:IKT-001PRO
  • Sponsor:Inhibikase Therapeutics Inc.

A study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

Study of the efficacy and safety of depigmented polymerized grass pollen extracts for patients with allergic rhinitis and controlled asthma.

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dactylis Glomerata Pollen Extract
  • Sponsor:LETI Pharma S.L.U.

Study of Grass Pollen Extract and Olive Pollen Extract for Patients with Hay Fever and Asthma caused by Grass and Olive Pollen Allergies

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dactylis Glomerata Pollen Extract
  • Sponsor:LETI Pharma S.L.U.

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:Liquidia Technologies Inc.

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-142
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Maia

What the registry says about research in the country

01 Cardiovascular Research

Ongoing clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease. Research aims to evaluate innovative treatment approaches for reducing inflammatory markers in dialysis patients.

  • Cardiovascular outcomes in ESKD patients
  • Inflammatory biomarker reduction
  • Dialysis patient care optimization

These studies investigate the relationship between inflammatory markers and cardiovascular health in patients undergoing maintenance dialysis, potentially leading to improved treatment strategies for this vulnerable population.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.